79418-73-8

Upstream product

• 100-97-0 hexamethylenetetramine 
• 73943-41-6 2-fluoro-6-methoxyphenol 
• 37686-68-3 2-fluoro-3,4-dimethoxybenzaldehyde 
• 61338-95-2 2-fluoro-3,4-dihydroxybenzaldehyde 
• 76-05-1 trifluoroacetic acid 

Downstream Products

• 775352-20-0 3-cyclopentyloxy-2-fluoro-4-methoxy-benzaldehyde 
• 329217-72-3 2-fluoro-4-methoxy-3-trifluoromethanesulfonyl benzaldehyde 
• 775350-86-2 (4-chloro-phenyl)-(3-cyclopentyloxy-2-fluoro-4-methoxy-phenyl)-methanol 

Relevant academic research and scientific papers

CEPHEM COMPOUND HAVING CATECHOL GROUP

A compound of the formula: wherein X is -N=, -CH=, or the like; W is -CH2- or the like; U is -S- or the like; R1 and R2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like; R3/su

Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia

The present invention relates to compounds of Formula (I) which may be useful in the treatment of diseases, such as, metabolic disorders, dyslipidemia and/or hyperchloesterolemia: 1

Heterocyclic derivatives for the treatment of diabetes and other diseases

The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.

Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.

Structure-activity relationship studies directed toward improving the potency and metabolic stability of CDP-840 (3) resulted in the discovery of L-791,943 (11n) as a potent (HWB TNF-alpha = 0.67 microM) and orally active phosphodiesterase type 4 (PDE4) inhibitor. This compound, which bears a stable bis-difluoromethoxy catechol and a pendant hexafluorocarbinol, exhibited a long half-life in rat and in squirrel monkey. It is well tolerated in ferret with an emetic threshold greater than 30 mg/kg (po) and was found to be active in the ovalbumin-induced bronchoconstriction model in guinea pig and in the ascaris-induced bronchoconstriction models in sheep and squirrel monkey.